Skip to main content

Posters

    • Predictors of NGS Testing in Metastic Colorectal Cancer (mCRC)
    • Outcomes Research on Regenerative Medicine in the United States
    • Cost Effectiveness Analysis of Antidepressants on Breast Cancer Patients: A Markov Modeling Study
    • Pharmacist-Provided Diabetes Education and Care Via Telemonitoring: The Utah Remote Monitoring Project
    • Quality of LIfe Outcome of the US Chronic Myeloid Leukemia (CML) Patients
    • Patterns and Outcomes of Treatment in Pediatric Patients with Clostridium Difficile Infection (CDI)
    • Where Do Veterans Receive their Care for Non-Traumatic Bone Fractures
    • An Observational Analysis Evaluating Outcomes in Cancer Patients Admitted to a Surgical (SICU) or Medical ICU (MICU) Compared to a Newly Opened Cancer Specific ICU (HICU)
    • Calculating the Baseline Fracture Incidence in Non-Risk Patients: A Strategy for Cost-Effectiveness Modeling
    • Cost-Effectiveness Analysis of Treatment Strategies for Initial Clostridium Difficile Infection
    • Cost-Effectiveness Analysis of the Threshold for Initial Hypertension Treatment- A Markov Study Evaluating JNC8 Guidelines
    • Cost-Effectiveness Analysis of MRI Guided Ablation Based on the DECAAF Trial
    • Cost-Effectiveness of Using a Prognostic Test to Guide Treatment Decisions in Early Stage Non-Small Cell Lung Cancer (NSCLC)
    • ICD-9 Codes and the Identification of Non-Tuberculous Mycobacteria Infections
    • Private Health Insurance and Risk Protection: Changes in Out-of-pocket Medical Spending, 2001 and 2005
    • Research in Progress: Information Seeking by Pharmacist in the Electronic Health Record (INSPIRE) study
    • Use of Concomitant Antibiotics During Treatment for Clostridium Difficile Infection (CDI) in Pediatric Inpatients
    • Excess Length of Stay Attributable to Clostridium Difficile Infection (CDI) in the Acute Care Setting: A Multi-State Model
    • A Dashboard for Health Information Exchange Between Poison Control Centers and Emergency Departments: The Poison Control Center View
    • Cost-Utility Analysis of a Prognostic Test for Early Stage Non-Small Cell Lung Cancer (NSCLC)
    • Clinical and Economic Outcomes of a Collaborative Diabetes Management Program in an Employer-Sponsored Family Medicine Clinic
    • Evaluation of Diabetes Outcomes After Implementation of Clinical Pharmacist Services in an Employer-Sponsored Family Medicine Clinic
    • Estimated Statin Treatment in Adopting ACC/AHA Guidelines in an Employer Based Primary Care Clinic
    • Clinical and Economic Impact of a Pharmacist-Led Diabetes Collaborative Drug Therapy Management Program in a Medicaid ACO Setting
    • Characteristics of Platinum-Sensitive Recurrent Ovarian Caner Patients by BRCA Status in an Academic Cancer Center
    • Evaluation of Aspirin Prescribing Practices for Primary Stroke Prevention in Women over the Age of 65 at an Academic Family Medicine Clinic
    • Outcomes in Cancer Patients Admitted to a Surgical (SICU) or Medical ICU (MICU) Compared to a Newly Opened Cancer Specific ICU (HICU)
    • Overall Survival and Complications of Cancer Therapy in HIV-Positive Cancer Patients on HAART Compared to HIV-Negative Cancer Patients
    • The Can: A Repository of Decision Support Rules Relating to Laboratory Tests
    • Risk Factors for Recurrent Clostridium Difficule Infection (CDI) in Pediatric Inpatients
    • Instance-Based Matching of FDA Established Pharmacologic Class (EPC) Concepts to the Anatomical Therapeutic Chemical (ATC) Classification System
    • Qualitative Analysis of Public-Domain Drug Hierarchies for Haboring FDA Established Pharmacologic Class (EPC) Concepts
    • Medication Reconciliation in a Senior Clinic: Impact of PharmD Students on Patient Care
    • Association between bisphosphonate switching behavior and cost outcomes in postmenopausal United States veterans
    • Literature Review and Assessment to Populate a Decision-Analytic Model Evaluating a Novel Prognostic Test in Early Lung Cancer
    • Cost and Length of Stay Associated with Vancomycin-Induced Nephrotoxicity
    • Evaluation of Variable Relevance and Accessibility to Support Personalized Medicine in Breast Cancer
    • Oral Anticoagulant Discontinuation in Patients with Nonvalvular Atrial Fibrillation
    • A Comparison of Demographic and Clinical Variables of Down Syndrome Patients in Utah and the United States
    • Survey of smoking cessation practices among Utah pharmacists
    • Development of an outpatient out-of-network, pegfilgrastim charting system
    • Clinic-based methadone vs. office-based buprenorphine: A cost effectiveness analysis

     

    • DuVall SL, Nebeker JR. VA Informatics and Computing Infrastructure (VINCI). University of Maryland, Baltimore County Center for Hybrid Multicore Productivity Research (CHMPR) Semi-Annual Industry Advisory Board Meeting. Baltimore, MD; December 17-19, 2012.
    • Schmier J, Cifaldi MA, Shaw JW, Halpern MT, Nickman NA. Hospital infusion center costs for anti-tumor necrosis factor agents. [Poster] ASHP 47th Annual Midyear Clinical Meeting and Exhibition, Las Vegas NV. December 4, 2012.
    • Onufrak N, Stevens V, Forrest A, Brown J. Association between Vancomycin AUC24/MIC and Attainment and Time-to-Clinical Cure among Patients with Enterococcal Bloodstream Infections. [Poster] ASHP 7th Annual Midyear Clinical Meeting and Exhibition, Las Vegas NV. December 4, 2012.
    • Coon S, Stevens V, Brown J, Wrobel M. (December 4, 2012). Comparison of product knowledge and confidence between pharmacists and health food store employees. [Poster] ASHP 47th Annual Midyear Clinical Meeting and Exhibition, Las Vegas NV. December 4, 2012.
    • Bossard W, Brown J, Albanese N, Slazak E, Stevens V. Anti-diabetic Agents and the Risk of Clostridium Difficile Infections. [Poster] ASHP 47th Annual Midyear Clinical Meeting and Exhibition, Las Vegas NV. December 4, 2012.
    • Patterson OV, DuVall SL. Advanced Concept Mapping to RadLex using the MetaMap Engine. RSNA Scientific Assembly and Annual Meeting, Chicago, IL; November 25-30, 2012.
    • Potter JM, Halls CH, Malohi BK, DuVall SL. Project Management and Coordination: Selecting Communication Tools for Multi-Site, Multidisciplinary Collaboration. American Medical Informatics Association (AMIA) Annual Symposium, Chicago, IL; November 16-20, 2012.
    • Cornia R, Patterson OV, DuVall SL. JMX Analysis Module: Multi-thread aggregate NLP performance monitoring. AMIA Annual Symposium, Chicago, IL; November 16-20, 2012.
    • Forbush TB, Adams B, Shen S, South BR, Nebeker JR, DuVall SL. CASPR: Friendly Annotation Management. AMIA Annual Symposium, Chicago, IL; November 16-20, 2012.
    • Suo Y, Shen S, DuVall SL, Uzuner O, South BR. Evaluation and Visualization of Human Annotator Learning Patterns. AMIA Annual Symposium, Chicago, IL; November 16-20, 2012.
    • Baddley J, Yang S, Brizendine K, DuVall SL, Winthrop KL, Burton MJ, Patkar NM, Delzell ES, Safford MM, Singh JA, Navarro IE, Cannon GW, Mikuls TR, Chen L, Saag KG, Alexander K, Napalkov P, Kamauu AWC, Curtis JR. Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy. ACR / ARHP 2012 Annual Scientific Meeting, Washington, DC; November 9-14, 2012.
    • Navarro-Millan I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, Delzell ES, Zhang J, Safford MM, Patkar NM, Mikuls TR, Singh JA, Curtis J. Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration. ACR / ARHP 2012 Annual Scientific Meeting, Washington, DC; November 9-14, 2012.
    • Kerr GS, Richards JS, Nunziato CA, Patterson OV, DuVall SL, Maron DD, Amdur RL. Natural Language Processing in the Evaluation of Gout Quality Indicators. ACR / ARHP 2012 Annual Scientific Meeting, Washington, DC; November 9-14, 2012.
    • McAdam-Marx C, Jennings BT, Dahal A, Gunning K. Pharmacist-led diabetes chronic care management program improves glycemic control without increasing costs in patients with uncontrolled type 2 diabetes. American College of Clinical Pharmacy Annual Meeting. Hollywood, FL. October 21-24, 2012.
    • McAdam-Marx C, Jennings BT, Dahal A, Gunning K. Pharmacist-led diabetes collaborative drug therapy management program improves glycemic control in patients with uncontrolled type 2 diabetes treated with insulin. American College of Clinical Pharmacy Annual Meeting. Hollywood, FL. October 21-24, 2012.
    • Jahn B, Stenehjem D, Saverno K, Cai B, Siebert U, Brixner DI. Preliminary Outcomes Towards a Risk-Based Microsimulation Decision- Model based on Treatment and Cost Inputs From a Real World Cohort of Breast Cancer Patients. [Poster] The 34th Annual Meeting of the Society for Medical Decision Making. Phoenix, AZ. October 17 - 20, 2012.
    • Stenehjem D, Kuo K, Bauer H, Barney R, Albright F, Brixner DI. Outcomes and treatment patterns of hepatocellular carcinoma patients stratified by staging-guided treatment categories in a patient-centered retrospective research registry. [Poster] ISPOR 5th Asia-Pacific Conference. Taipei, Taiwan. September 2012.
    • Stenehjem D, Albright F, Guo A, Chen L, Raimundo K, Bauer H, Brixner DI. Assessing real-world response monitoring and tolerability of imatinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP) and A chart review analysis of monitoring and patterns of treatment switching in patients with chronic myeloid leukemia in chronic phase (CML-CP) on imatinib. [Poster] 14th International Conference CML- Biology and Therapy. Baltimore, MD. September 20-23, 2012.
    • Marcus RL, Ghate S, Brixner DI, LaStayo P. Relative Sarcopenia and Not Absolute Sarcopenia Impacts Physical Performance in Non-Obese Older Adults. [Poster] The Gerontological Society of America. Albuquerque, NM. July 12-13, 2012.
    • Saverno K, Rochau U, Schmidt S, Stenehjem D, Kallinger S, Gastl G, Brixner DI, Siebert U. Comparison of Chronic Myeloid Leukemia Registries in Austria and Utah, USA. [Poster] 9th Annual Meeting of Health Technology Assessment International. Bilbao, Spain. June 23-27, 2012.
    • Oderda G, Holtorf AP, Brixner DI. Health Economic and Outcomes Research (HEOR) Evidence in Health Technology Assessment (HTA) for Drug Formulary and Reimbursement Decisions across Global Regions. [Poster] HTAi Annual Meeting. Bilboa, Spain. June 23-27, 2012.
    • Brixner DI, Watkins JB, Oderda G, Sifford-Wilson SM, Biskupiak JE, Dunn JD, Holtorf AP. This drug may work, but is it worth the cost? can comparative effectiveness research help tame rising health care costs? J Manag Care Pharm. 2012 June 18(5 Supp A):S1-S29.
    • Brixner DI, Watkins JB. Can CER Be an Effective Tool for Change in the Development and Assessment of New Drugs and Technologies? J Manag Care Pharm. 2012 June 18(5 Supp A):S1-S29.
    • Jahn B, Brixner DI, Saverno K, Rochau U, Stenehjem D, Albright F, Siebert U. Application of Real World Data to Inform A Decision -Analytic Model in Breast Cancer in Austria and the U.S. [Poster] Biennial European Meeting of the Society for Medical Decision Making, 14th. Oslo, Norway. June 10-12, 2012.
    • Stenehjem D, Albright F, Saverno K, Rochau U, Siebert U, Brixner DI. Real World Data Inform a Decision Analytic Model in Breast Cancer in Austria and the U.S. [Poster]14th Biennial European Meeting of the Society for Medical Decision Making (SMDE Europe 2012) Oslo, Norway. June 10-12, 2012.
    • Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Lackner M, Sroczynski G, Schall I, Schnell-Inderst P, Flatscher-Thni M, Gothe H, Pugner K, Brixner DI, Siebert U. Do existing cost-effectiveness thresholds adequately support decision making for PCM? A review of international practice. [Poster] 14th Biennial European Meeting of the Society for Medical Decision Making (SMDE Europe 2012) Oslo, Norway. June 10 -12, 2012.
    • Bellows BK, Ye X, Unni S, Mukherjee J, Iloeje U, McAdam-Marx C. Impact of Anti-diabetic Drug Selection on Weight Change and HbA1c Outcomes in Treatment Nave Patients with Type 2 Diabetes. [Poster] American Diabetes Association 2012 Scientific Sessions, Philadelphia PA. June 8-13, 2012. Included in Guided Audio Poster Tour.
    • Bellows BK, Dahal A, Jiao T, Biskupiak J. A cost-utility analysis of pregabalin vs. duloxetine in painful diabetic neuropathy. Value Health. 2012;15(4):A181. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting. Washington, D.C. June 4, 2012
    • Ghate S, Porucznik C, Said Q, Joy EA, Hashibe M, Brixner DI. Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting. Washington, D.C. June 4, 2012.
    • Stenehjem D, Albright D, Gou A, Chen L, Raimundo K, Bauer H, Brixner, DI. Real-world response monitoring and tolerability of imatinib treated chronic myeloid leukemia patients captured in a retrospective research registry. [Poster] ASCO Meeting. Chicago, IL. June 4, 2012.
    • Stenehjem D, Albright F, Kuo K, Raimundo K, Brixner DI. Evaluating Contemporary Practice in CML via a Retrospective Research Registry of Patients across a Comprehensive Cancer Center Database. International Society For Pharmacoeconomics and Outcomes Research, 17th Annual International Meeting. Washington, DC. June 1-6, 2012.
    • LaFleur J, Nelson RE, Hoop R, Pandya P, Morgan T, Hayden C, Yao Y, Hamzeh F. Discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. International Liver Congress 2012: 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain. April 2012.
    • Zhang J, Tian H, Gorsh B, Lin J, Goodman M. Prescription of inhaled corticosteroids and GOLD severity stage among patients with chronic obstructive pulmonary disease. AMCP's 2012 Educational Conference. San Francisco, CA. April 2012.
    • Dye J, Bellows B, Holtorf A, Brixner DI. Use of Pharmacoeconomic and Outcomes Research in Formulary Decision Making: A Tale of Two Surveys [Poster] AMCP Meeting. San Francisco, CA. April 16-19, 2012.
    • Bellows B, McAdam-Marx C, Unni S, Ye X, Mukherjee J, Brixner DI. 12-month HbA1c and Weight Outcomes by Drug Class in Treatment Nave Patients with Type 2 Diabetes. [Poster] AMCP Meeting. San Francisco, CA. April 16-19, 2012.
    •  
    • Brixner DI, Mukherjee J, McAdamMarx C. "Weight loss of 3% or more in a 12-month period is associated with glycaemic control in newly treated type 2 diabetes patients in the usual care setting." 47th EASD Annual Meeting, Lisbon, Portugal, September 2011.
    • Goodman M. "The Use of the Internet to Generate Adverse Event Hhypotheses." International Society for Pharmacoepidemiology Research, Chicago, IL. August 2011. (Poster)
    • Young JR, Oderda LH, Asche, CV, Pepper, GA. "Antipsychotic Medications and Risk of Falls Leading to Hip Fracture in Older Adults" Center on Aging Research Retreat Poster Session. Salt Lake City, UT February 2011. (Poster)
    • Heise B, Asche CV, Oderda LH. "RAISE Elderly: Readiness of Older Adults to Use a Personal Health Record" Center on Aging Research Retreat Poster Session. Salt Lake City, UT February 2011. (Poster)
    • Asche C. "Health Economics and Compliance of Vials/Syringes Versus Pen Devices: A Review of the Evidence" Western Pharmacoeconomics Conference 2011, Seattle WA, April 2011.
    • Nickman N, McAdam-Marx C. "An Evaluation of Bone Density Screening and Technology Frequency (2005-2008) among US Women age 50 and older in a commercial medical claims database" AACE American Association of Clinical Endocrinologist 2011Annual Meeting, San Diego CA, April, 2011.
    • McAdam-Marx C, Oderda GM. "Bootstrapping used to provide robust mean and variance estimates for comparing patients treated Liraglutide to a large comparison cohort" ISPOR 16th Annual International Meeting, Baltimore MD, May 2011.
    • McAdam-Marx C, Oderda GM. "Baseline characteristics and antidiabetic exposure in patients with type 2 diabetes treated with Liraglutide", ISPOR 16th Annual International Meeting, Baltimore MD, May 2011. (Poster)
    • McAdam-Marx C, Oderda GM. "Research on Methods: Economic Evaluations" ISPOR 16th Annual International Meeting, Baltimore MD, May 2011.
    • Albright F, Brixner DI. "Baseline Results from a 6 Cancer HER Retrospective Study" American Society Clinical Oncology, Chicago IL, June 2011.
    • Brixner DI. "Better Evidence, Better Decision: Enhancing Your P&T Committee Using Comparative Effectiveness Research" American Society of Health Systems Pharmacist, Denver CO, June 2011.
    • Goodman M. "Use of Internet to generate adverse event hypothesis" ISPE International Society of Pharmacoepidemiology 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago IL, Aug 2011.
    • LaFleur J. "TBA" ASBMR American Society for Bone and Mineral Research 33rd Annual Meeting Chicago IL, Sept 2011.
    • Albright F, Bollu V, Kuo K, Raimundo K, Barney R, Stenehjem D, Brixner D. "Integrating Data Sources to Conduct Comprehensive Oncology based Outcomes Research." Podium presentation at ISPOR 2011, Baltimore, MD & poster presentation at Western Pharmacoeconomics Conference 2011, Seattle, WA
    • McAdam-Marx C, Jennings B, Sayler M, Gunning K. "An Evaluation of Clinical and Economic Outcomes Associated with a Pharmacist-Coordinated Diabetes Chronic Care Management Program." 2011 American Association of Colleges of Pharmacy Annual Meeting. July 10, 2011. San Antoinio, TX.
    • McAdam-Marx C, Unni S, Nelson S, Ye X, Nickman N. "An evaluation of bone mineral density screening and technology frequency (2005-2008) among US women age 50 and older in a commercial medical claims database." 17th Annual Meeting of the International Society of Clinical Densitometry. April 6-9, 2011, Miami, FL. (Recipient of the ISCD New Investigator Award.)
    • Yu J, Smith K, Brixner D. (In Press). Cost-Effectiveness of Pharmacotherapy for the Prevention of Migraine: an Application of Markov Model. CNS Drugs.
    • McAdam Marx C, Bouchard J, Aagren M, Nelson R, Brixner D. (In Press). Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting [Abstract]. Diabetes, Obesity and Metabolism.
    • Kwong J, Cho S, Ghate S, Brixner DI, Fox E. Adverse Outcomes Following Substitution of Warfarin Products in Atrial Fibrillation Patients [Poster Presentation] 45th ASHP Midyear Clinical Meeting & Exposition. Anaheim, CA. December, 2010.
    • Brixner DI Evaluation of Support Services to Colorectal Cancer Patients in Mexico [Poster Presentation] ISPOR 13th Annual European Congress Prague, Czech Republic November, 2010.
    • Brixner DI Current and Future Use of Pharmacoeconomic and Outcomes Research Data in Decision Making in the USA. [Poster Presentation] ISPOR 13th Annual European Congress Prague, Czech Republic November 2010.
    • Asche CV, Kim J, Chakravarti P. "Assessment of Association of Increased Heart Rate to Cardiovascular Events Among Healthy Patients" International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual European Congress, Prague, November, 2010. (Poster)
    • Asche CV, Kim J, Chakravarti P*. "Assessment of Association of Increased Heart Rate to Cardiovascular Events Among Healthy Patients" International Continence Society (ICS/IUGA) Annual Meeting, Toronto, Ontario, 2010. (Poster)
    • Kim J, Asche CV, Kahler K, Kulkarni A*, Andersson K. "Assessment of Association of Increased Heart Rate to Cardiovascular Events Among Healthy Patients" Canadian Urology Association (CUA) 2010 Annual Meeting, P.E.I. (Poster)
    • Yu J*, Asche CV, Fairchild C. "The Economic Burden of Dry Eye in the United States: A Decision Tree Analysis Model", Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, Georgia, 2010. (Poster)
    • Asche CV, Shane-McWhorter L, Raparla S*. "Health economic and Compliance of vial/syringe vs. pen devices", 6th Annual Utah Health Services Research Conference, Salt Lake City, Utah, 2010. (Poster)
    • Asche CV. "Assessment of Comorbidities in Patients with Overactive Bladder Disorder: An Electronic Medical Record (EMR) Data Analysis." International Continence Society and International Urogynecological Association 2010 Joint Annual Meeting Aug 23-27, 2010 Toronto, Ontario, Canada. (Poster)
    • Pepper MJ, Shane-McWhorter, Bellows B, McAdam-Marx C, Albright F, Osborne B. "Exercise in Hispanic patients with type 2 diabetes mellitus: can a Spanish exercise DVD help?" American Association of Diabetes Educators Annual Conference, August 7-10, 2010, San Antonio, TX.
    • Asche CV. "Utilization of the Chronic Kidney Disease Epidemiology Collaboration Equation to Measure the Impact of Elevated Intact Parathyroid Hormone on Mortality and Renal Disease Progression in Patients with Stage 3 and 4 Chronic Kidney Disease." European Renal/Dialysis Transplant Association Congress 2010 June 25-28, 2010. Munich, Germany. (Poster)
    • McAdam-Marx C, Brixner DI. Approach To Matching Alzheimer's Disease Patient and Their Spouses to Assess Caregiver Burden in an Administrative Claims Database. [Poster Presentation] ISPOR 15th Annual International Meeting. Atlanta, GA. May-15-19, 2010.
    • Dhamane AD, Martin B, Brixner DI, Hudson TJ, Said Q. (2010) Assessment of Metabolic Monitoring of Patients Prescribed Second Generation Antiphyshotics (SGAS) Using Electronic Medical Record (EMR) Data. [Poster Presentation] 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 15-19, 2010. Atlanta, GA. (Poster)
    • Tasic D, Brixner DI, Goodman MJ. "The Impact of Oral Antidiabetics on Weight in the Elderly with Type 2 Diabetes Mellitus in the Ambulatory Setting." 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 15-19, 2010. Atlanta, GA. (Poster)
    • Nickman NA, Haak SW, Kim JW. "Use Of Clinical Simulation Centers To Conduct Patient-Centered Time-And-Motion Simulations As A Basis For Economic Analysis" 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 17, 2010. Atlanta, GA. (Poster)
    • Kim J, Nickman N. Comorbidities, quality of life, and US healthcare access by risk cohort characteristics of people calculated using Framingham risk percent from the US national health and nutrition examination survey (NHANES). 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 19, 2010, Atlanta, Georgia USA. (Poster)
    • Kim J, Nickman N. "Spatial Dependence (Or Cluster) In Total Number Of Prescription Drugs Filled At Retail Pharmacies In US" 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 18, 2010. Atlanta, GA. (Poster)
    • Brixner DI, McAdam-Marx C, Van Den Bos J, Perlman D. "Approach to Matching Patients with Alzheimer's Disease and their Spouse to Control Patients in Spouses in an Administrative Claims Database". 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 18, 2010. Atlanta, GA. (Poster)
    • Asche CV, Yu J. "Economic Burden of Dry Eye Syndrome in the U.S.: Application to a Decision Tree Analysis Model." 15th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 18, 2010 Atlanta, GA. (Poster)
    • Brixner DI, McAdam-Marx C, Van Den Bos J, Perlman D. "Costs One Year Post Diagnosis for Alzheimer Patients and their Spouses vs. Matched Controls." 2010 American Geriatrics Society Annual Scientific Meeting May 13, 2010. Orlando, FL. (Poster)
    • Brixner DI, McAdam-Marx C, Van Den Bos J, Perlman D. "Resource Use for Caregivers vs. Matched Controls One-Year Pre vs. Post Patient Diagnosis for Alzheimer Disease." 2010 American Geriatrics Society Annual Scientific Meeting May 13, 2010. Orlando, FL.
    • Biskupiak J. "Blood pressure outcomes associated with the use of ARBs in a primary care electronic medical record database." American Society of Hypertension 2010 Annual Scientific Meeting and Exposition May 1-4, 2010 New York, NY.
    • Goodman MJ. "Relationship between Body Mass Index and Muscle Mass among the Elderly (Age>64 years)" American Geriatrics Society Annual Scientific Meeting - May 12-15, 2010. Orlando, FL
    • Brixner DI, Goodman MJ. "Comparing Adherence Measures against One-Year Outcomes for Patients with Epilepsy" AMCP 22nd Annual Meeting & Showcase April 7-10, 2010. San Diego, CA.
    • Asche CV, Shane-McWhorter L, Raparla S. "Health Economics and Compliance of Vial/Syringe Versus Pen Devices: A Review of the Evidence." 6th Annual - Utah Health Services Research Conference, University of Utah, April 2010.
    • LaFleur J, Nelson RE, Sauer BS, Sheng X, Pickard S, Ong SH, Brixner DI, Nebeker J. "Any-cause hospitalization outcomes associated with poor patient adherence to antihypertensives" [podium presentation]. 2nd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia, and Diabetes Mellitus. Valencia, Spain. December 2009.
    • Kim J, Asche CV, Yaldo A*, Panish J, Ascher S, Dirani R. "The Economic Impact of Switching Treatment from Risperidone to Paliperidone ER, Aripiprazole, Olanzapine, Ziprasidone or Quetiapine" [poster]. U.S. Psychiatric & Mental Health Congress, Las Vegas, Mandalay Bay Convention Center. November 2009.
    • Biskupiak J, Kim J. "A Comparison of Blood Pressure Outcomes Associated with the Use of ARBs in Patients Seen Predominantly in Primary Care Practices" [poster] ISPOR 12th Annual European Congress, Paris, France. October 2009.
    • Asche C*, Marx SE, Jaewhan K, Sterz R, Audhya P. "Impact of Elevated Intact Parathyroid Hormone (iPTH) on Mortality and Renal Disease Progression in Patients with Stage 3 and 4 Chronic Kidney Disease (CKD)" [poster]. ASN Renal Week, San Diego, California. October 2009.
    • McAdam-Marx C, Nelson R, Aagren M, Bouchard J, Brixner DI. "Analysis of glycaemic control outcomes vs. baseline in patients treated with analog basal insulin in a real-world setting". International Diabetes Federation 20th World Diabetes Congress. Montreal, Canada. October 2009.
    • McAdam-Marx C, Yu J, Shankar V, Bouchard J, Aagren M, Brixner DI. "Average daily dose of analog basal insulins in patients with type 2 diabetes: a matched case control analysis". International Diabetes Federation 20th World Diabetes Congress. Montreal, Canada. October 2009.
    • LaFleur J, Nelson RE, Pickard S, Nebeker J. "A risk stratification rule for at risk of fracture based on clinical and administrative data." American Society of Bone and Mineral Research 31st Annual Meeting. Denver, Colorado. September 2009.
    • Asche C, Jhaveri M*, Nelson R, McAdam-Marx C, Ye X. "Predictors of Oral Bisphosphonate Treatment Amongst Post-Menopausal Women with Low Bone Mineral Density or an Osteoporosis Diagnosis in a Real World Setting"[poster]. American Society of Bone and Mineral Research 31st Annual Meeting. Denver, Colorado. September 2009.
    • Golden W, Bigal ME, Yu J, Hu XHenry, Brixner D, Lipton RB, LaFleur J. "Acute Treatment of Migraine in Patients with Cardiovascular Disease or Risk Factors" [poster]. 14th International Headache Congress. Philadelphia, PA. September 2009.
    • Golden W, Bigal ME, Yu J, Hu XH, Brixner D, Lipton RB, LaFleur J. "Patterns of Acute Medication Use in Individuals with Cardiovascular Disease or Risk Factors" [poster]. 14th International Headache Congress. Philadelphia, PA. September 2009.
    • Augustovski F*, Asche C*, Pinto D*, Bosi Ferraz M*, Contreras Hernandez I*. "Reimbursement Review Process Across Latin America" (Educational Symposium), 2nd Annual Latin American Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Rio de Janeiro, Brazil. September 2009.
    • Ghate SR, Biskupiak J, Casciano J, Hagan M, Brixner DI. "Rate of Bleeding Events and Comorbidities among Atrial Fibrillation Patients Treated With or Without Warfarin". 25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ISPE). Rhode Island. August 2009.
    • Kim J, Asche C, Kahler K, Kulkarni A*. "Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) Disorder in a Real-World Setting"[poster]. 25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ISPE). Rhode Island. August 2009.
    • Brixner D, McAdam-Marx C, Nelson R, Aagren M, Bouchard J. "Analysis of glycemic control and weight changes in patients treated with analog basal insulin in a real-world setting". American Diabetes Association, 69th Annual Scientific Meeting. New Orleans, LA. June 2009. (Published Abstract)
    • Fabunmi R, McAdam-Marx C, Ye X, Misurski D, Brixner D. "Blood Pressure Outcomes after 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study". American Diabetes Association, 69th Annual Scientific Meeting. New Orleans, LA. June 2009.
    • Kim J, Phatak H, Biskupiak J, Wu D, "Assessment Of The Status Of Hypertension Management In Newly Diagnosed And Established Hypertension Patients In Primary Care Practice". 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
    • Kim J, Asche CV, Anderson KH, Kahler KH, Kulkarni A, "Assessment Of Cardiovascular (CV) Comobidity In Patients With Overactive Bladder (OAB) Disorder In A Real-World Setting"[poster]. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
    • McAdam-Marx C, Yu J, Shankar V, Bouchard J, Brixner DI. Daily Average Consumption of Basil Insulin in Patients with Type 2 Diabetes. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
    • Kim J. Finite Mixture Regressions in Modeling Prescription Drug Utilization and Prescription Drug Expenditures of Patients with Rheumatoid Arthritis (Ra). 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
    • McAdam-Marx C, Brixner DI, X Ye, Misurski D, Fabunmi R. A1C and Weight Outcomes Following 6 Months of Analog Basal Insulin in Insulin Na�ve Patients with Type 2 Diabetes in an Ambulatory Care Setting. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
    • Brixner DI, McAdam-Marx C, X Ye, Misurski D, Wintle M, Fabunmi R. 18 month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type 2 Diabetes in a Real-World Study. 14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
    • Kim J, Asche CV. Pharmacological Side Effects of Antimuscarinic Drugs on Heart Rate: GEE and Multilevel Approaches. 5th Annual Utah Health Services Research Conference. (Podium Presentation) Salt Lake City, UT. May 2009.
    • Yu J, Brixner DI, Ghate S, Gordon K. A Pilot Study of Screening Outcomes in Patients at Risk for Athrosclerosis in the Utah Community Clinics. 5th Annual Utah Health Services Research Conference (Podium Presentation) Salt Lake City, UT. May 2009.
    • Kim J, Biskupiak JE, Phatak H, Wu D. Assessment of the Presence of High Risk Cardiovascular Conditions and the Status of Hypertension Management among Elderly Adults in the US Primary Care Practices. 5th Annual Utah Health Services Research Conference. (Podium Presentation) Salt Lake City, UT. May 2009.
    • Oderda GM, McAdam-Marx C, Cleveland J, Roland CL. Direct Costs of Opioid Abuse in Medicaid Patients. AMCP 21st Annual Meeting & Showcase. Orlando, FL. April 2009.
    • Kim J, Asche CV, Kahler K, Kulkarni A. Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) Disorder in a Real-World Setting. Western Pharmacoeconomics Conference 2009. Pasadena, California. March 2009.
    • Nelson RE, LaFleur J, Pickard SG, Nebeker JR. Predictors of Bisphosphonate Treatment in Male United States Veterans. Western Pharmacoeconomics Conference 2009. Pasadena, California. March 2009.
    • LaFleur J, Nelson R, Pickard S, Nebeker J. "Gathering evidence for clinical decision support in male osteoporosis in veterans" [podium presentation]. 2009 University of Utah Center on Aging Research Retreat. Salt Lake City, Utah. March 2009.
    • Kim J, Biskupiak J. "Assessment Of The Status Of Hypertension Management In Newly Diagnosed And Established Hypertension Patients In Primary Care Practice". Western Pharmacoeconomics Conference 2009. Pasadena, California. March 2009.
    • Nelson RE, LaFleur J, Pickard S, Nebeker J. "Predictors of an osteoporosis diagnosis in male United States veterans" [podium presentation]. 2009 Western Pharmacoeconomics Conference. Palo Alto, California. Pasadena, California. March 2009.
    • McAdam-Marx C, Yu J, Shankar V, Bouchard J, Brixner DI. "Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes". Western Pharmacoeconomics Conference 2009. Pasadena, California. March 2009.
    • LaFleur J, Nelson R, McAdam-Marx C, Pickard S, Nebeker J. "Electronic clinical and administrative data can be used to predict patients at risk of fragility fracture" [podium presentation]. 2009 HSR&D (Health Services Research and Development) National Meeting. Baltimore, Maryland. February 2009.
    • Brixner DI, Malone, D, Watkins J. Advancing the Use of Real World Data in Formulary and Reimbursement Decision Making. AMCP 2008 Educational Conference. Kansas City, MO. October 2008.
    • LaFleur J, McAdam-Marx C, Pickard SG, Nebeker JR. Recognition and treatment of male osteoporosis is low. ASBMR 30th Annual Meeting, Montreal, Montreal, Canada, September 2008.
    • Brixner DI, Oderda G, Ye X, Boye KS, Wintle M, Fabunmi R. Clinical Effectiveness of Exenatide in Patients with Type 2 Diabetes in a Primary Care Electronic Medical Record Database. American Diabetes Association 68th Scientific Sessions. San Francisco, CA. June 2008.
    • Nelson RE, Lafleur J, McAdam-Marx C, Brixner DI, Ward R. Patent extension policies for pediatric indications: an evaluation of the impact within one drug class in one state Medicaid program. Academy Health 2008 Annual Meeting. June 2008. Washington, DC.
    • Shafazand S, Yang Y, Mitsi G, Brixner DI. Heart Failure Quality of Care: Views from a Nationwide Administrative Claims Database. American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke, Baltimore, Maryland, May 2008.
    • Nickman NA, Haak SW, Harald EA, Holtorf AP, Joshi AV, Kim JW, Brixner DI. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • Roper M, Biskupiak J, Alder S, Oderda G. Comparison of Men Age 21 Years and Older with and w/out Erectile Dysfunction on Concomitant Prescription Drug, Comorbid Conditions, Smoking Status and BMI. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • Brixner DI, McAdam-Marx C, Biskupiak J, Lau HJ, Munger M. Association of Adverse Events of Antihypertensive Therapy by Age in a Physician Practice National EMR Database. American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke, Baltimore, Maryland, May 2008.
    • McAdam-Marx C, Brixner DI, Field R, Metraux S. Type 2 Diabetes in Youth: 2002 and 2006 Prevalence and Obesity in a Primary Care Setting. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • McAdam-Marx C, Brixner DI, Oberg B. Estimation of Study Population Size for Effectiveness Outcomes at 6 and 12 months via Electronic Medical Records. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • McAdam-Marx C, Brixner DI, Ye X, Sung JC, Kahler KH. Evaluation of Resistant Hypertension in a Usual-Care Setting. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • Nelson R, McAdam-Marx C, Misurski DA, Nielsen LL. Descriptive analysis of body weight and clinical effectiveness measures associated with type 2 diabetes therapies in a primary care electronic medical record database. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • Ghate SR, Said Q, Huse D, Ben-Joseph R, Brixner DI. Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight US Primary Care Patients. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • LaFleur J, Ghate SR, Sauer B. Updating The RxRisk-V: Creating A Crosswalk Between VA And Firstdatabank Therapeutic Categories. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • LaFleur J, Ghate SR, Ye X. Estimating Sociodemographic Variables In A Pharmacy Dataset: Applying Data From Us Census 2000. 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • Ghate SR, LaFleur J, Charland SL, Sauer B. A Modified Rxrisk-V Comorbidity Index Predicts Adherence With Lipid Lowering Therapy (LLT). 13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada, May, 2008.
    • Hassanein TI, Ye X, Blumentals WA, Brixner DI. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. Digestive Disease Week, San Diego, California, May, 2008.
    • McAdam-Marx C, Brixner DI, Asche C. Identifying potential adverse events in an electronic medical record database. 4th Annual Utah Health Services Research Conference. April 25, 2008. Salt Lake City, UT.
    • Hassanein TI, Ye X, Blumentals WA, Brixner DI. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Phoenix, Arizona, April, 2008.
    • Ghate SR, Doan J, Nelson R, Van Den Bos J, Brixner DI. Indirect Costs Associated with Patients Treated for Insomnia: An Employer Perspective. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Phoenix, Arizona, 2008, April, 2008.
    • Hassanein TI, Ye X, Blumentals WA, Brixner DI. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. 43rd Annual Meeting European Association for the Study of the Liver (EASL), Milan, Italy, April, 2008.
    • Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 1st Latin America Conference, Cartagena, Columbia, 2007.
    • Kane S, Magowan S, Accortt N, Brixner DI. Predictors of 5-ASA Prescription Persistence During the Chronic Phase in Patients with Ulcerative Colitis. American College of Gastroenterology Annual Scientific Meeting, Philadelphia, Pennsylvania, 2007.
    • Brixner DI, Jackson K, Sheng X, Biskupiak J, Keskinaslan A. Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Conference, Dublin, Ireland, 2007.
    • Asche CV, Seal B, McAdam-Marx C, Crookston B, Svejda R, Mullins CD. Treatment costs associated with community acquired pneumonia by community level antimicrobial resistance. ISPOR 10th Annual European Congress. October 20-23, 2007; Dublin, Ireland.
    • Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Association between oral antidiabetic adverse events and outcomes in a real world setting. ADA 67th Specific Meeting. 2007 June; Chicago, IL 2126-PO.
    • McAdam-Marx C, Brixner D, Metrau S, Chan V, PharmD3, Field R. Determinants of race and ethnicity reporting for youth with health data in an electronic medical record database. University of the Sciences Scholarly Day. 18 April, 2007. Philadelphia, PA.
    • LaFleur J, Asche CV, McAdam-Marx C, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. 3rd Annual Utah Health Services Research Conference, Friday April 6, 2007, Salt Lake City, UT.
    • LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, Brixner D, Silverman S. "Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting" [poster]. The American Society of Bone and Mineral Research 29th Annual Meeting. Honolulu, Hawaii. September 2007.
    • LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, Brixner D, Silverman S. " The risk of clinical vertebral fracture for postmenopausal patients with specific combinations of fracture risk factors in a primary-care setting" [poster and abstract]. 7th International Symposium on Osteoporosis: Translating Research into Clinical Practice. Washington, D.C. April 2007. Osteoporosis International 2007; 18(Supplement 2):S210.
    • LaFleur J, McBeth C, Steinvoort C, Oderda L, Paul M, Gunning K, Oderda G. "Identification and categorization of drug-related problems among Medicaid patients: Variability between pharmacist reviewers". American College of Clinical Pharmacy 2007 Spring Practice and Research Forum. Memphis, Tennessee. April 2007. Pharmacotherapy 2007;27(4):31.
    • Atherton A, LaFleur J, Mayeda B, Oderda L, Oderda GM. "Comparison of drug-related problems in nursing home residents versus non-nursing home Medicaid patients". American College of Clinical Pharmacy 2007 Spring Practice and Research Forum. Memphis, Tennessee. April 2007.
    • Holtorf A-P, LaFleur J, Servatius D, Jeffries B, Brixner DI. "Prescription drug use by women and men in Utah Medicaid". Utah Health Services Research Meets Public Health Informatics. Salt Lake City, Utah. April 2007.
    • Holtorf A-P, LaFleur J, Servatius D, Jeffries B, McBeth C, Brixner DI. "Statin treatment of diabetic patients in Utah Medicaid". Utah Health Services Research Meets Public Health Informatics. Salt Lake City, Utah. April 2007.
    • Nickman NA, Haak SW, Holtorf AP, Joshi AV, Brixner DI. Time-and-motion evaluation of different growth hormone formulations. ISPOR 10th Annual European Congress, Dublin, Ireland: October 2007.
    • Biskupiak J, Brixner DI, Keskinaslan A. Effectiveness of Multiple-Mechanism Antihypertensive Medication: Valsartan-Amlodipine-HCTZ Triple-Therapy in Primary Care. ISPOR 10th Annual European Congress, Dublin, Ireland, Oct 2007.
    • Biskupiak J, Brixner DI, Munger M, Keskinaslan A. Effectiveness of Amlodipine Valsartan Combination Therapy in Primary Care. European Society of Hypertension, 17th European Meeting on Hypertension, Milan, Italy, June 2007.
    • Jackson K, Brixner DI, Oderda G, Oberg B, Sheng X, Keskinaslan A. Compliance and Economic Outcomes with Valsartan and HCTZ Combination Therapy for Hypertensive Patients. American Society of Hypertension, June 2007.
    • Kane S, Magowan S, Accortt N, Brixner DI. Predictors of 5-ASA Prescription Persistence in Patients with Ulcerative Colitis. Digestive Disease Week 2007, Washington, D.C., May 2007.
    • Brixner DI, Magowan S, Accortt N. Prescription Refill Behavior for Nifedipine Therapy is Significantly Dependent on Medication Cost. 8th American Heart Association Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, D.C., May 2007.
    • Brixner DI, Ghate SR, McAdam-Marx C, Ben-JosephR, Said Q. Correlation of Weight to Cardiometabolic Risk as Identified by ICD-9 Diagnosis Codes and Prescriptions in Primary Care. International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 2007.
    • Brixner DI. Contraceptive and non-contraceptive benefits of a Levonorgestrel-releasing intrauterine in a vertically integrated HMO. International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 2007.
    • Brixner DI, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. Academy of Managed Care Pharmacy 19th Annual Meeting & Showcase, San Diego, California, April 2007.
    • Brixner DI, Said Q, Oderda G, Kirkness C. Assessment of the clinical risk factors for cardiometabolic risk in a national primary care electronic medical record (EMR) database. Academy of Managed Care Pharmacy 19th Annual Meeting & Showcase, San Diego, California, April 2007.
    • Nickman NA, Haak SW, Holtorf AP, Joshi AV, Brixner DI. Time-and-motion evaluation of different growth hormone formulations. ISPOR 10th Annual European Congress. October 2007; Dublin, Ireland.
    • Asche CV, Machado M, Caro J. "ISPOR Digest of International Databases for Pharmacoeconomics and Outcomes Research" 1st Annual Latin American Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Cartagena, Columbia, 2007.
    • Asche CV, Young D, Brixner DI, Phillips A. "Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database" American College of Clinical Pharmacy (ACCP) 2007 Spring Practice and Research Forum, Memphis, TN, April 21 � 25, 2007.
    • Asche CV, Mucha L, Lenhart G, Seal B. "Incremental Costs Associated Antibiotics Prescribed for Community Acquired Pneumonia Episodes" 12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, 2007.
    • Mucha L, Seal B, Lenhart G, Asche CV. "Direct and Incremental Costs of Acute Respiratory Infections" 12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, 2007.
    • Seal B, Mucha L, Lenhart G, Asche CV. "Incremental Costs Associated with Antibiotics Prescribed for Acute Otitis Media" 12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, 2007.
    • Asche CV, McAdam-Marx C, Shane-McWhorter L, Plauschinat C. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. Utah Health Services Research Conference, VA Salt Lake City Health Care System, Salt Lake City, UT, 2007.
    • Asche CV, Oderda LH, Pepper GA. "The Economic Impact of Treatment of Falls-Related Injuries from a U.S. Employers Perspective" Center on Aging Research Retreat, Salt Lake City, UT, 2007.
    • Asche CV, McAdam-Marx C, Shane-McWhorter L, Plauschinat C. "Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting" American Diabetes Association (ADA), Chicago, IL, 2007.
    • Asche CV, Cummings G. "ISPOR Digest of international databases for pharmacoeconomics and outcomes research" 10th Annual European Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Dublin, Ireland, 2007
    • Oderda G, Lieberman M, Asche CV, Brixner DI. "Use of electronic medical record (EMR) data in outcomes research" 10th Annual European Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Dublin, Ireland, 2007.
    • Ghate SR, Kirkness C, Biskupiak J. Assessment of Comorbidities and Prevalence in Patients with GERD using the GE EMR Database. Submitted and presented at the Second Western Pharmacoeconomics Conference, Salt Lake City, UT 2007.
    • Asche CV, Brixner DI, L'Italien GJ. "Pharmacoeconomic Research in Latin America: Gathering the Data for Dossier Requirements" 1st Annual Latin American Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Cartagena, Columbia, 2007.
    • Asche CV, Young D, Brixner DI, Phillips A. Assessment of asthma/chronic obstruction pulmonary disease (COPD) outcomes via databases. 72nd Annual international, assembly of the American College of Chest Physicians (ACCP). Chest. October 21-26, 2006. SLC, UT.
    • Brixner DI, Joish VM, McAdam-Marx C, Arondekar B, Hoblyuk R. Evaluation of Persistence and Outcomes in Patients on SU Combination Therapy with TZDs or Metformin. In AMCP 18th Annual Meeting. 2006 April. Seattle Washington.
    • Brixner DI, Nickman N, Oderda GM. Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community based oncology practices. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Asian Congress May 2006, Shanghai, China.
    • McGarry LJ, Iskander R, Seal B, Asche CV, Thompson D, Weinstein MC. Cost-effectiveness of telithromycin in the treatment of community acquired pneumonia. 11th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research. Philadelphia, PA 2006.
    • Haak S, Nickman N, Rusho W, Beck S, LaFleur J, Brixner D. Joint Professional Analysis of a Novel Dosage form in the Intensive Care (ICU) Setting. American Association of Critincal Care Nurses; May 2006, Anaheim, California.
    • LaFleur J, Oderda GM, Lyon JL, White G. The Case of Lipid-Lowering Therapy: A Comparison of Adherence Measurement Methodologies Using Administrative Claims Data. 11th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research. Philadelphia, PA. May 2006.
    • McAdam-Marx C, Joish VN, Brixner DI, Hoblyuk R. A Comparison of Adherence and Cost of Sulfonylureas in Combination with TZDs or Metaformin. ADA 66th Specific Meeting. 2006 June; Washington D.C.
    • Oderda GM, Said Q, Evans RS, Stoddard GJ, Rublee D, Lloyd J, Samore MH. Opioid-related Adverse Drug Events in Surgical Hospitalizations: Impact on Costs and Length of Stay. 25th Annual Scientific Meeting. American Pain Society. May 2006. San Antonio, Texas.
    • LaFleur J, Asche CV, McAdam-Marx C, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. American Society of Health-System Pharmacists. 41st Mid-Year Meeting. December 3-7, 2006 Anaheim, CA.
    • Asche CV, McAdam-Marx C, Share-McWhorter L, Plauschinat CA. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. American Society of Health-System Pharmacists. 41st Mid-Year Meeting. December 3-7, 2006 Anaheim, CA.
    • Brixner DI, McAdam-Marx C, Gallwitz W, Roper M, Asche CV. Value of Reducing Vertebral Fractures in Women with Post-Menopausal Osteoporosis with Multiple Clinical Risk Factors for Fracture Based on the TOP Study. American Society of Health-System Pharmacists 41st Midyear Clinical Meeting, Anaheim, California, December 2006.
    • Brixner DI, Ghate SR, McAdam-Marx C, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 9th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research, 2006, Copenhagen Denmark.
    • Asche CV, Brixner DI, Conoscenti CS, Young D, Shah H, Phillips AL. Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database, American College of Chest Physicians Meeting, Salt Lake City, Utah, October 2006.
    • Asche CV, Stockdale W, Pepper G, Gallagher EM. The Economic Impact of Treatment of Falls-Related Injuries. Canadian Association of Population Therapeutics; Vancouver, British Columbia, 2005.
    • Asche CV, Oderda G. Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. College of Pharmacy Research Symposium; University of Utah, Salt Lake City, Utah, 2005.
    • Asche CV, Stockdale W, Pepper G, Gallagher EM. The economic impact of treatment of falls-related injuries from a U.S. Employers Perspective. International Association of Gerontology, Rio de Janeiro, Brazil, 2005.
    • Biskupiak JE, Brixner DI, Oderda GM, Howard K. Gastrointestinal Complications of over-the-counter non-steroidal anti-inflammatory drugs. ACG 70th Annual Scientific Meeting; October Honolulu, HI, 2005.
    • Brixner DI, Nickman N, Oderda GM. Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community based oncology practices. International Society of Pharmacoeconomics and Outcomes Research (ISPOR), 8th European Congress, October Florence, Italy, 2005.
    • Brixner DI, Said Q, Newcomer J, Tuomari V, Oderda GM, Stockdale WA, L'Italien GJ. Real world usage of weight gain drugs in patients on second-generation anti-psychotics. American Psychiatric Association. Atlanta, GA, 2005.
    • Brixner DI, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Rome Italy, 2005.
    • Brixner DI, Said Q, Newcomer J, Tuomari V, Oderda GM, Stockdale W, L'Italian. Diagnostic Coding for Patients on Second Generation Antipsychotics in Real World. American Psychiatric Association; Atlanta, GA, 2005.
    • Brixner DI, Ho MJ, Sauer BC, Stockdale WA. Development of an integrated diabetes database across community clinics and hospitals. International Society of Pharmacoeconomics and Outcomes Research, Washington, D.C., 2005.
    • Brixner DI, Blonde L, Said Q, Tuomari V, Oderda GM, Corey-Lisle PK, L'Italian GJ. Real World Impact of Second Generation Antipsychotics on Weight Gain. American Diabetes Association, San Diego, CA, 2005.
    • Carter O, MacCarter D, Mannebach S, Biskupiak J, Stoddard G, Giblert EM, Munger MA. D-Ribose improves peak exercise capacity and ventilatory efficiency in heart failure patients. JACC 2005; 45(Suppl A):185A.
    • Haak S, Nickman NA. Nursing and Pharmacy Collaboration in Use of Simulation for Time and Motion Study. Nursing Learning Resource Center Conference, Villanova University, Philadelphia, PA. 2005.
    • Joish VN, Brady E, Stockdale WA, Dirani R, Brixner DI. Identification and diagnosis of COPD in a primary care setting. International Conference American Thoracic Society; San Diego, CA. 2005.
    • Joish VN, Brixner DI, LaFleur J, Kirkness C. Pharmacoeconomic analysis of ARB therapy in patients with mild-to-moderate hypertension. Academy of Managed Care Pharmacy 2005 Educational Conference; Nashville, TN.
    • Joish VN, Stockdale WA, Brady E, Dirani R, Brixner DI. An assessment of diagnosis and treatment of COPD in primary care via an electronic medical record database. International Society of Pharmacoeconomics and Outcomes Research; 2005.
    • LaFleur J, Thompson CJ, Joish VN, Charland S, Oderda GM, Brixner DI. Adherence and persistence with lipid-lowering pharmacotherapy: Effects of the covariates copay and disease severity on probabilities of being categorized as compliant. Pharmacotherapy Outcomes Research Center; Kos Pharmaceuticals, Inc.
    • LaFleur J, Fowler MA, McBeth C, Oderda L, Gunning K, Steinvoort C, Stockdale W, Oderda GM. Prevalence of drug-related problems among Medicaid high utilizers as identified by clinically-trained pharmacist reviewers American College of Clinical Pharmacy 2005 Spring Practice and Research Forum and Updates in Therapeutics. Myrtle Beach, South Carolina, 2005.
    • Lipman AG, Jackson KC, Stockdale W, Oderda GM. The Treatment Outcomes of Pain Survey (TOPS): A Validated Health Related Quality of Life (HRQoL) Outcomes Instrument for Research and Practice. 11th World Congress on Pain. International Association for the Study of Pain. Sydney, Australia, 2005.
    • Maio V, Yuen E, Brixner D, Oderda G, Asche CV, Smith K.D, Morgan S. Multi-national assessment of outcomes via retrospective databases, Healthcare Policy Development Issues, Contributed Workshops, International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 8th European Congress, October, Florence, Italy, 2005.
    • Oderda G, Asche CV, Stockdale W, Spalding J. (2005). Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. 13th Annual Congress on Women's Health Congress; Hilton Head Island, SC.
    • Roland C, Biskupiak J. Number of intrathecal pumps being used for chronic intractable pain. American Pain Society 24th Annual Scientific Meeting; Boston, Massachusetts, 2005.
    • Said Q, Ho MJ, Beckwith MC, Brixner DI. A Pharmacoeconomic comparison of Oral Fluoroquinolones for Complicated Urinary Tract Infections. Academy of Managed Care Educational Conference; Denver, CO, 2005; Academy of Managed Care Educational Conference, Nashville, Tennessee, 2005.
    • Brixner DI, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. National Osteoporosis Foundation, Sixth International Symposium on Osteoporosis, Washington, D.C., 2005.
    • LaFleur J, Thompson C, Ho MJ, Stockdale WA, Charland S, Oderda GM, Brixner DI. Adherence, persistence, and cost of lipid-lowering pharmacotherapy: ER-niacin/statin combination therapy within a single dosage-form versus two separate dosage forms in a managed care population.
    • Brixner DI, Ho MJ, Sauer BC, Stockdale WA. Real world usage of weight gain drugs in patients on second-generation antipsychotics. American Diabetes Association, 2005.
    • Asche CV, Stockdale W, Pepper G, Gallagher EM. The economic impact of treatment of falls-related injuries. Canadian Association of Population Therapeutics, 2004.
    • Brixner DI, Tabb K. Overview of databases used in managed care research. 9th Annual Meeting, International Society of Pharmacoeconomics and Outcomes Research; Washington, DC, 2004.
    • Brixner D, Asche CV, Chang J, Stewart J, Paladino JA. Economic value of telithromycin vs clarithromycin in the treatment of community-acquired pneumonia. 39th American Society of Health-System Pharmacists (ASHP), Midyear Clinical Meeting; Orlando, Florida, 2004.
    • Brixner DI, Cannon HE, Oderda GM, Stockdale WA, Joish VN, Hanson D. Impact of varying copays on patient prescribing behavior in a managed care organization: focus on hypertension. Academy of Managed Care Pharmacy 16th Annual Meeting and Showcase; San Francisco, CA, 2004.
    • Christensen RL, LaFleur J, Ho MJ, Joish VN, Brixner DI. Which HMG-CoAreductase inhibitor for hyperlipiemia: a cost-effectiveness analysis based on the STELLAR trial. Academy of Managed Care Pharmacy 16th Annual Meeting and Showcase; San Francisco, CA, 2004.
    • Ho MJ, LaFleur J, Brixner D. What is the Cost for Atypical Antipsychotics for Schizophrenia: Efficacy versus Effective Doses [poster].Academy of Managed Care Pharmacy 2004 Educational Conference; Baltimore, Maryland, 2004.
    • Ho MJ, LaFleur J, Brixner DI. Which atypical antipsychotics for schizophrenia: cost-efficacy versus cost-effectiveness analyses. Academy of Managed Care Pharmacy; Baltimore, MD, 2004.
    • Ho MJ, Joish VN, LaFleur J, Christensen RL, Brixner DI. Which oral triptan for migraine: a cost-efficacy analysis from a managed care perspective. Academy of Managed Care Pharmacy 16th Annual Meeting and Showcase; San Francisco, CA, 2004.
    • Ho MJ, Joish VN, Stockdale W, Oderda GM, Alder S, White G. Does recommended self-blood glucose monitoring impact overall healthcare resource use. American Society of Health-Systems Pharmacists, 39th Midyear Clinical Meeting, Orlando, Florida, 2004.
    • Joish VN, Malone DC, Wendel C, Mohler MJ. Development of a diabetes resource consumption index (DRCI): a risk adjustment toll for predicting healthcare resource use and costs. Value in Health. 2004.
    • Joish VN, Donaldson G, Stockdale WA, Oderda GM, Brixner DI, Sasane R, Joshua-Gotlib S, Crawely JA. Economic burden of GERD and PUD in an employed population. 9th Annual Meeting International Society of Pharmacoeconomics and Outcomes Research; Arlington, VA, 2004.
    • LaFleur J, Beckwith C, Fowler M, Tyler L, Brixner D. A Pharmacoeconomic Comparison of Oral Third-Generation Cephalosporins for Acute Otitis Media [poster]. American Society of Health-System Pharmacy 39th Midyear Clinical Meeting. Orlando, Florida, 2004..
    • LaFleur J, Thompson C, Ho MJ, Stockdale WA, Charland S, Oderda GM, Brixner DI. Adherence, persistence, and cost of lipid-lowering pharmacotherapy: ER-niacin/statin combination therapy within a single dosage-form versus two separate dosage forms in a managed care population. Academy of Managed Care Pharmacy; Baltimore, MD, 2004.
    • LaFleur J, Oderda G, Stockdale W, Gunning K, Orlando P, Steinvoort C, Tyler L. Impact of Pharmacist Reviews on Prescribing Behavior. ACCP Spring Meeting; Paris, France, 2004.
    • Oderda GM, LaFleur J, Gunning K, Stockdale W, Orlando P, Steinvoort C. Impact of Structured Patient Reviews of High Prescription Utilizers on the Cost of Care. American College of Clinical Pharmacy (ACCP) and European Society of Clinical Pharmacy Joint, Spring Meeting; Paris, France, 2004.
    • Oderda GM, LaFleur J, Gunning K, Stockdale W, Orlando P, Steinvoort C. Reducing Drug Costs via a Structured Review of High Utilizers in the Utah Medicaid Program. ACCP Spring Meeting; Paris, France; April 2004.
    • Oderda L, Young E, Oderda G. Graduate Employability: A Longitudinal Comparison of Preceptors' Opinions about Hiring Clerkship Students After Multiple Professional Experiences: 2000-2003. American Association of Colleges of Pharmacy Meeting; Salt Lake City, Utah, 2004.
    • Stockdale WA, Brixner DI. Comorbidity influence index. 9th Annual Meeting International Society of Pharmacoeconomics and Outcomes Research; Arlington, VA, 2004.